Member Info for busicat

EC,

HASU=Hyper-acute Stroke Unit

Morning Digitalis

Adding to musings on the rollercoaster, I was surprised the sell off caused by the rush to cash profits and dive into AFC took the price no lower than it did yesterday and whether logically or not, I'm encouraged to see the late reported trade being:

04-Jun-25 16:38:22 75.27 275,000 Buy* 69.40 70.90 206.99k O

I'd be very happy to approach 75p again in the short term.

1.7 you mean! Heh, heh! ; )

Same post is on Genedrive's LinkedIn this morning too.

Well spotted MillionAir - thanks for sharing

"We are delighted that both of our pharmacogenetic tests are now available for order via the NHS supply chain!"

https://bsky.app/profile/genedrive.bsky.social

https://bsky.app/profile/genedrive.bsky.social

The big picture of Dr John McDermott's presentation: The PROGRESS programme has recruited patients from 20 sites across England following prescription of common medicines - statins, opioids, antidepressants, and proton pump inhibitors - and pharmacogenomic guidance was returned, integrated into the electronic healthcare record. The proportion of patients with an actionable variant related to their medicine was recorded, along with prescription amendments, turnaround times and compliance with guidance.

Whilst investor are impatient to see commercial progress, clinicians are spreading the story of what's being achieved across pharmacogenomics. This nice write up of Dr. John McDermott's presentation about integrating genomic data into electronic health records at the annual congress of the European Society of Human Genetics in Milan on Tuesday features the TIA testing example of how prescribing based on genomic testing is already making a difference:

"Large-scale interventions like this need to be justified from a health economic perspective, Dr McDermott says. “There have been several studies showing the potential value of pharmacogenomics, which have typically focussed on specific drugs, specific genes, and specific clinical scenarios. For example, the UK's National Institute for Health and Care Excellence (NICE) have recently recommended that all patients who have had a stroke or a transient ischaemic attack (TIA) should undergo pharmacogenomic testing to guide the choice of antiplatelet therapy. This was based on a health economic assessment which demonstrated a potential value to the health system of hundreds of millions of pounds in prevented strokes and gained quality of life.” "

https://bioengineer.org/promising-outcomes-from-nhs-progress-study-highlight-the-integration-of-pharmacogenomic-guided-prescribing-into-routine-clinical-practice/

9% up and no excitement here today?

Hi EC

Thought you'd like to see the nice comment by an NHS project manager added on GDR'sLinkedIn generic post today about how they can help with stroke outcomes where clopidogrel-resistance applies:

"Worth mentioning I think too in the current CYP2C19 pilot study, 134 patients were tested in Salford using the Genedrive test and 42 (i.e 31%) were identified as poor metabolisers. "

...which I understand is in line with previous studies.

Happy weekend : )

I think Jimi is right - it looks like Alastair's spouse has jumped onto his LinkedIn account. Alastair himself seems to have been a "good leaver" going by the last few months where he has been adding "likes" on LinkedIn in support of Genedrive.

Well, I'm hearing and surmising nothing about a contract incoming, but did enjoy the CEO's post enought to pop in a little top up (shown as a sell).

The "buckle up" conclusion to the post doesn't mean anything other than we've got a great product and it's an exciting ride, IMHO. But then he's clearly upbeat on how the ATS meeting went in San Francisco, and why not?

Judge for yourselves:

"Finally did it—rode in a Waymo with no driver this week during the annual American Thoracic Society (ATS) meeting in San Francisco.

Strange? Yes. Smooth ride? Surprisingly. Sang at the top of my lungs? Absolutely—no driver to judge.

Between the great Xenon MRI talks and energizing meetings at ATS, the ride reminded me: just like autonomous taxis, the Polarean Xenon MRI once felt futuristic. But now we are delivering FDA-approved, non-invasive, radiation-free, functional lung imaging scans in just 10 seconds—helping clinicians see what traditional pulmonary tests may miss.

The future shows up fast. Sometimes it even sings back. Buckle up! "

Whoops, correcting my ramble about today's price 5 mins ago, I've gone back to see nearly everything I said was rubbish! The only cheery thing (for me!) was getting my mini buy at 1.29 (not 1.229!) and finding the bid has at least reached 1.3.

As you were, everybody.

Returning to see what happened in reaction to the news (and price drop), since the 2nd transaction (shown as a sell) was my mini buy at 1.229, the upward flow of prices for the later deals look like buys too, even though shown in red, so I take a bit of comfort in that for this unpopular share.

£4,720k (H1 2024: £729k) orderbook sounds fab, but from cash of about £1m(?), if period end bank balance was £512k (H1 2024: £759k), reason to be nervous?

Ongoing delay with the significant defence contract, from which revenue was originally expected to commence by this time. seems to be a problem!

"Highlights

£000 FY25 FY24 YOY % change

Revenue 18,386 16,274 13%

Gross profit 13,763 11,947 15%

Gross margin % 75% 73% +2ppts

Underlying EBITDA 1,151 80 1,339%

Profit/(loss) before tax 720 (384) -

Basic EPS (pence) 0.38 0.05 660%

Diluted EPS (pence) 0.36 0.04 800%

Closing cash 10,912 11,868 (8)%1 ["cash balance up to £12.7m at the end of April 2025"]

Financial Highlights

· Financial performance improved notably in H2, driven by a higher proportion

of high-value sales and increasing demand across cloud computing, defence

and satellite markets.

· Improved gross margin, reflecting the increased revenue volumes and

product mix in the year.

· Strong balance sheet with closing cash position of£10.9m (31 March 2024:

£11.9m), £2.3m ahead of the cash position at the half year, reflecting H2

cash generation.

· Closing trade receivables balance of £5.3m after strong Q4 trading. Majority

of balance received in April 2025, with total cash position increasing to

£12.7m at 30 April 2025.

· Cost control measures taken through the year also contributed to the return

to profit.

· Proposed final dividend of 0.62p per share. Total of 0.93p per share for FY25

(FY24: 0.93p)."

GDR exchibiting at the European Stroke Organisation Conference this week, which is billed as Europe’s leading forum for advances in research and clinical care of patients with cerebrovascular diseases and expects >4,500 attendees from around the world.

In March's update they did say "The Company's review of strategic options is ongoing and as a consequence of this, it is expected that the Final Results for the year ended 31 December 2024 will be announced later than in prior years, and a results date and an update on the review of strategic options will be announced in due course."

...but in the strategic options review update in April, no further comment was added about timing of results.

Waking up at last?

Not only has legs, but breaking into a gallop, SmokinJoe

Excellent! Thanks for posting ShearClass.